Goldman Sachs Group Inc Summit Therapeutics Inc. Transaction History

Goldman Sachs Group Inc

$780 Billion
Q3 2025

A detailed history of Goldman Sachs Group Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 497,547 shares of SMMT stock, worth $9.08 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

497,547

Previous 303,426 63.98%

Holding current value

$9.08 Million

Previous $6.46 Million 59.76%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$17.61 - $30.02 $3.42 Million - $5.83 Million	194,121 Added 63.98%	497,547 $10.3 Million
Q2 2025 Aug 14, 2025	SELL	$16.64 - $36.7 $4.48 Million - $9.89 Million	-269,365 Reduced 47.03%	303,426 $6.46 Million
Q1 2025 May 16, 2025	SELL	$16.65 - $23.76 $651,015 - $929,016	-39,100 Reduced 6.39%	572,791 $11 Million
Q1 2025 May 09, 2025	SELL	$16.65 - $23.76 $4.96 Million - $7.08 Million	-298,111 Reduced 32.76%	611,891 $11.8 Million
Q4 2024 Feb 11, 2025	BUY	$17.52 - $23.46 $7.26 Million - $9.73 Million	414,647 Added 83.71%	910,002 $16.2 Million

Q3 2024 Nov 14, 2024	BUY	$6.89 - $31.93 $285,321 - $1.32 Million	41,411 Added 9.12%	495,355 $10.8 Million
Q2 2024 Aug 13, 2024	SELL	$2.39 - $10.92 $541,710 - $2.48 Million	-226,657 Reduced 33.3%	453,944 $3.54 Million
Q1 2024 May 15, 2024	BUY	$2.55 - $5.07 $1.24 Million - $2.46 Million	486,193 Added 250.09%	680,601 $2.82 Million
Q4 2023 Feb 13, 2024	BUY	$1.67 - $2.83 $3,690 - $6,254	2,210 Added 1.15%	194,408 $507,000
Q3 2023 May 14, 2024	SELL	$1.54 - $2.42 $3,403 - $5,348	-2,210 Reduced 1.14%	192,198 $359,000
Q3 2023 Nov 14, 2023	SELL	$1.54 - $2.42 $244,558 - $384,305	-158,804 Reduced 45.24%	192,198 $359,000
Q2 2023 May 14, 2024	SELL	$1.32 - $2.81 $118,650 - $252,582	-89,887 Reduced 20.39%	351,002 $881,000
Q2 2023 Aug 14, 2023	SELL	$1.32 - $2.81 $118,650 - $252,582	-89,887 Reduced 20.39%	351,002 $881,000
Q1 2023 May 14, 2024	BUY	$1.38 - $5.41 $531,821 - $2.08 Million	385,378 Added 694.24%	440,889 $771,000
Q1 2023 May 11, 2023	BUY	$1.38 - $5.41 $531,821 - $2.08 Million	385,378 Added 694.24%	440,889 $771,000
Q4 2022 May 14, 2024	SELL	$0.68 - $5.31 $3,555 - $27,765	-5,229 Reduced 8.61%	55,511 $235,000
Q4 2022 Feb 13, 2023	SELL	$0.68 - $5.31 $3,555 - $27,765	-5,229 Reduced 8.61%	55,511 $235,000
Q3 2022 May 14, 2024	BUY	$0.89 - $1.63 $23,448 - $42,945	26,347 Added 76.61%	60,740 $72,000
Q3 2022 Nov 10, 2022	BUY	$0.89 - $1.63 $23,448 - $42,945	26,347 Added 76.61%	60,740 $0
Q2 2022 May 14, 2024	SELL	$0.92 - $2.38 $147,213 - $380,835	-160,015 Reduced 82.31%	34,393 $34,000
Q2 2022 Aug 15, 2022	SELL	$0.92 - $2.38 $2,193 - $5,673	-2,384 Reduced 6.48%	34,393 $34,000
Q1 2022 May 16, 2022	SELL	$2.0 - $3.45 $20,626 - $35,579	-10,313 Reduced 21.9%	36,777 $90,000
Q4 2021 Feb 14, 2022	BUY	$2.45 - $5.64 $13,563 - $31,223	5,536 Added 13.32%	47,090 $126,000
Q3 2021 Nov 10, 2021	BUY	$4.83 - $8.27 $200,705 - $343,651	41,554 New	41,554 $208,000

Others Institutions Holding SMMT

# of Institutions

264

Shares Held

94.3M

Call Options Held

4.72M

Put Options Held

4.03M

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $3.67B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Summit Therapeutics Inc. Transaction History